RT Journal Article
SR Electronic
T1 Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1349
OP 1351
VO 31
IS 7
A1 Mori, Takehiko
A1 Kameda, Hideto
A1 Ogawa, Hiroe
A1 Iizuka, Atsushi
A1 Sekiguchi, Naoya
A1 Takei, Hirofumi
A1 Nagasawa, Hayato
A1 Tokuhira, Michihide
A1 Tanaka, Toshio
A1 Saito, Yumiko
A1 Amano, Koichi
A1 Abe, Toru
A1 Takeuchi, Tsutomu
YR 2004
UL http://www.jrheum.org/content/31/7/1349.abstract
AB OBJECTIVE: To evaluate the incidence and effect of cytomegalovirus (CMV) reactivation in patients with inflammatory connective tissue diseases (CTD) undergoing immunosuppressive therapy. METHODS: A total of 18 consecutive CMV seropositive patients undergoing immunosuppressive therapy for inflammatory CTD were enrolled. CMV reactivation was determined by detection of CMV-DNA in peripheral blood leukocytes (PBL) or plasma using quantitative real-time polymerase chain reaction. RESULTS: CMV reactivation was detected in PBL in 7 of 17 evaluable patients (41%), and in plasma in 5 of 17 patients (29%). Patients with detectable CMV-DNA in plasma were exclusively positive for CMV-DNA in PBL. Conclusion. Patients with inflammatory CTD under immunosuppressive therapy are at high risk for CMV reactivation. The clinical significance of such an event and indications for antiviral therapy should be examined further.